D6070c00001- A Phase 1 Multicenter, Open-Label, Dose-Escalation And Dose-Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Immunogenicity, And Antitumor Activity Of Medi9447 Alone And In Combination With Durvalumab In Adult Subjects
Posted Date: May 15, 2019
- Investigator: Trisha Wise-Draper
- Specialties: Cancer, Lung Cancer, Pancreatic Cancer
- Type of Study: Drug
To assess the safety and tolerability, describe any dose-limiting toxicity (DLT), and determine the MTD or the highest protocol-defined dose for oleclumab when administered as a single agent and in combination with durvalumab in subjects with selected advanced solid tumors.
Criteria:
To Be Eligible: Age 18 Or Older, Nonpregnant/Nonbreastfeeding, Must Have Crc, Pancreatic Adenocarcinoma, Or Nsclc, No Uncontrolled Current Illness Or Malignancy Within 2 Years
Keywords:
Pancreatic Cancer, Nsclc, Phase I, Solid Tumor
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com